Hamamatsu University School of Medicine
Hamamatsu, Shizuoka, 431-3192, Japan
NCT Number: NCT00197457
Helicobacter pylori (H. pylori) eradication increases the serum pepsinogen (PG) I/PG II ratio and the percentage change in PG I/PG II ratios was found to be a useful marker of H. pylori eradication (e.g., the PG method). We studied whether the PG method could be an early diagnostic marker of H. pylori eradication even in patients persistently treated with a proton pump inhibitor. Sixty-two H. pylori-positive patients underwent H. pylori-eradication therapy, followed by treatment with a PPI to cure ulcers. Serum levels of PG I and PG II were measured before, at the end of, and at 4 weeks after the eradication therapy. At more than one month after the end of treatments, 13C-urea breath test (UBT) was performed. The cut-off values of percentage changes in PG I/PG II ratios for the diagnosis of eradication of H. pylori were set in proportion to PG I/PG II ratios before eradication in accordance with our previous report. Using the results of UBT as the standard, the percentage change in serum PG I/PG II ratios is useful as an early diagnostic marker for judgment of H. pylori eradication irrespective of PPI treatment.
Looking for future studies?
Notify Me20 year–90 year
All sexes
Interventional
Phase 2
Hamamatsu, Shizuoka, 431-3192, Japan
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hamamatsu University
Other
Serum Pepsinogens as an Early Diagnostic Marker of H. Pylori Eradication
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06045494
H. Pylori Infection
Hangzhou, Zhejiang, China
View Trial DetailsNCT07289451
H. Pylori Infection
Cairo, Egypt
View Trial DetailsNCT03340454
H. Pylori Infection
New York, United States
View Trial DetailsNCT06304532
H. Pylori Infection
Karachi, Sindh, Pakistan
View Trial Details